TPG-backed Pathology Asia invests Australia's Safe Work
TPG Capital Asia’s Pathology Asia platform has continued a regional roll-up strategy with an investment of undisclosed size in a minority stake in Australian drug testing specialist Safe Work Laboratories.
It follows the acquisition in July last year of a portfolio of 39 pathology laboratories across Singapore, Malaysia, and Vietnam from Australian hospital operator Healthscope for A$279 million ($200 million)....
More on Australasia
Latest News
Deal focus: Clearing up Southeast Asia’s currency chaos
Investors see opportunity in bringing a promising currency exchange-focused fintech model from Europe into Southeast Asia. Singapore-focused YouTrip is the region’s first mover in this niche
Governance standards: A matter of integrity
Traditionally the overlooked, underappreciated or misrepresented facet of ESG, governance is gaining prominence in emerging markets private equity as investors reassess risk exposure
China education: Passing the test?
Capital has poured into China’s online education sector in recent years, but with losses mounting and valuations called into question, investors are finding that not all business models are created equal
Endiya reaches $40m first close of second India VC fund
Endiya Partners, an early-stage VC investor based in India, has achieved a first close of $40 million for its second fund. The target is $70 million.